

VMC Pharmacy and Therapeutics Updates

July 2024 Decisions and Highlights

Medication Name or Topic Discussed	Decision Point	Indication	Mechanism of Action / Dosing	Comments and Go-Live Date
Bispecific antibodies (Epcoritamab-bysp, EPKINLY® and teclistamab-cqyy (TECVAYLI®))	Recommendation to develop a workgroup to determine next steps, including further reimbursement analysis and developing policies/procedure/protocols for bispecific administration at Valley. Will need to return to P&T for approval	Refractory diffuse large B-cell lymphoma or multiple myeloma who have failed 3 or more systemic treatments	Bispecific t-cell engaging antibodies that target CD3 or CD20 cells.	Workgroup met in late July and decided to submit request to project management team as next step. Currently is on hold given Infusion Center move/expansion.
Tafasitamab (MONJUVI®)	Add to formulary restricted to infusion center with appropriate prior authorization and utilized per NCCN guidelines	Refractory diffuse large B-cell lymphoma	Tafasitamab is a humanized CD19-directed, Fc-modified monoclonal antibody that binds to CD19 antigen, which is expressed on the surface several B-cell malignancies, including diffuse large B-cell lymphoma. <i>Dose: 12mg/kg given on various days depend on cycle</i>	Went live in July 2024
Lutetium Lu 177 dotatae (LUTATHERA®) and amino acid solution	Add to formulary , restricted to nuclear medicine/radiology oncology use only	Gastroenteropancreatic neuroendocrine tumors	Lutetium Lu 177 dotatae is a beta- and gamma-emitting radionuclide which binds to somatostatin receptors.. Beta emission induces cellular damage by forming free radicals in somatostatin receptor-positive and surrounding cells. <i>Dose: 200mCi every 8 weeks</i>	Go-live TBD
SCIP Antibiotic Guide Updates	Approved	SCIP recommendations updated to align with IDSA and Allergy society recommendations (particularly with use of cefazolin for most penicillin allergic patients, except for SJS or DRESS).		Order set tickets submitted, go-live TBD

For questions or more information, please contact Kamal Sandhu, PharmD – Clinical Pharmacy Manager and P&T Co-Chair
kamal_sandhu@valleymed.org